Tilt Biotherapeutics OY

Helsinki, Uusimaa Doing business as Tilt Biotherapeutics AB

UEI
MVBTSLK4AG17
CAGE
A829G
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
International Organization
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
Haartmaninkatu 8, 00290 Helsinki, Finland
Website
tiltbio.com
Founded
2013
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Tilt Biotherapeutics OY's latest federal award, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Unleashing the full potential of checkpoint inhibitor antibodies with t-cell-stimulating oncolytic adenoviruses for… Grant · HT94252310988 Defense Health Agency $2,098,194

Quick answers

What is Tilt Biotherapeutics OY's UEI?

Tilt Biotherapeutics OY's Unique Entity ID (UEI) in SAM.gov is MVBTSLK4AG17.

What is Tilt Biotherapeutics OY's CAGE code?

Tilt Biotherapeutics OY's CAGE code is A829G.

What is Tilt Biotherapeutics OY's primary NAICS code?

Tilt Biotherapeutics OY's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Tilt Biotherapeutics OY located?

Tilt Biotherapeutics OY's physical address in SAM.gov is Haartmaninkatu 8, 00290 Helsinki, Finland.

Is Tilt Biotherapeutics OY registered in SAM.gov?

Yes. Tilt Biotherapeutics OY's SAM.gov registration is active through September 3, 2027.

What is Tilt Biotherapeutics OY's most recent federal award?

Tilt Biotherapeutics OY's most recent federal grant award is Unleashing the full potential of checkpoint inhibitor antibodies with t-cell-stimulating oncolytic adenoviruses for… (HT94252310988), from Defense Health Agency, on September 1, 2023.

On GovTribe

See Tilt Biotherapeutics OY's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login